A randomised phase III study in advanced oesophageal carcinoma to compare dysphagia in patients treated with radiotherapy versus chemo-radiotherapy.

People with cancer of the oesophagus (gullet) often have trouble swallowing. Radiotherapy can help improve this problem. Using chemotherapy together with radiotherapy may work better but has more side effects. This trial will determine if it is better to use radiotherapy by itself or together with chemotherapy.

Primary Sponsor

Trans Tasman Radiation Oncology Group (TROG)

Collaborating Groups

NCI CTG (ES 2)

Final Accrual

220

Trial Chairperson

Dr Michael Penniment, Royal Adelaide Hospital, SA

Trial Contact

sonya.stephens@health.sa.gov.au

Clinical Trial Registration

Related Post

4 June, 2026

Report showcases a year of impactful research, collaboration and consumer engagement

LATEST NEWS: 4 June 2025 TROG’s latest Annual Research

ESTRO26 presentation
20 May, 2026

TROG trials in the spotlight at ESTRO26 international conference

LATEST NEWS: 20 MAY A number of TROG trials